SG11201809858RA - Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells - Google Patents

Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

Info

Publication number
SG11201809858RA
SG11201809858RA SG11201809858RA SG11201809858RA SG11201809858RA SG 11201809858R A SG11201809858R A SG 11201809858RA SG 11201809858R A SG11201809858R A SG 11201809858RA SG 11201809858R A SG11201809858R A SG 11201809858RA SG 11201809858R A SG11201809858R A SG 11201809858RA
Authority
SG
Singapore
Prior art keywords
cells
road
methods
international
myeloid leukemia
Prior art date
Application number
SG11201809858RA
Inventor
Steven Fischkoff
Uri Herzberg
Lin Kang
Brian Murphy
Andrea Nordberg
Vanessa Voskinarian-Berse
Keith Wilson
Xiaokui Zhang
Han Myint
Mohamed Hussein
Original Assignee
Celularity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celularity Inc filed Critical Celularity Inc
Publication of SG11201809858RA publication Critical patent/SG11201809858RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/196657 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 35/17 (2015.01) Cl 2N 5/0783 (2010.01) HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, A61P 35/00 (2006.01) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (21) International Application Number: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PCT/US2017/031255 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (22) International Filing Date: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 05 May 2017 (05.05.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/333,187 07 May 2016 (07.05.2016) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 62/333,186 07 May 2016 (07.05.2016) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 62/415,918 01 November 2016 (01.11.2016) US TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 62/415,954 01 November 2016 (01.11.2016) US KM, ML, MR, NE, SN, TD, TG). (71) Applicant: ANTHROGENESIS CORPORATION Published: [US/US]; 7 Powder Horn Drive, Warren, NJ 07059 (US). — with international search report (Art. 21(3)) (72) Inventors; and (71) Applicants: FISCHKOFF, Steven, Alan [US/US]; 5 Canoe Brook Road, Short Hills, NJ 07078 (US). HERZBERG, Uri [US/US]; 148 Maple Street, Bridge- water, NJ 08807 (US). KANG, Lin [CN/US]; 1106 Tim- ber Oaks Road, Edison, NJ 08820 (US). MURPHY, Bri- an [US/US]; 99 1/2 Greene Street, Apt. 1, Jersey City, NJ 070302 (US). NORDBERG, Andrea [US/US]; 162 Steuben Street, Apt. 3, Jersey City, NJ 07302 (US). VOSKINARIAN-BERSE, Vanessa [US/US]; 1670 Val- ley Road, Millington, NJ 07946 (US). WILSON, Keith [US/US]; 224 Old Tote Road, Mountainside, NJ 07092 (US). ZHANG, Xiaokui [US/US]; 68 Blazier Road, Mar- tinsville, NJ 08836 (US). MYINT, Han [US/US]; Edge- mere Road, Livingston, NJ 07039 (US). HUSSEIN, Mo- hamed [US/US]; 16107 Copeland Farms Road, Odessa, FL 33556 (US). Agent: GEORGE, Nikolaos, C. et al.; Jones Day, 250 (74) Vesey Street, New York, NY 10281-1047 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (81) ,_ 1 (54) Title: METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MULTIPLE MYELOMA USING NATURAL KILLER CELLS IN (57) : Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering in an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is ,t: produced by a three- stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising 01 stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting 1-1 --.... with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental Ir- perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the 1-1 C NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain ei embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL- 2. C
SG11201809858RA 2016-05-07 2017-05-05 Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells SG11201809858RA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662333187P 2016-05-07 2016-05-07
US201662333186P 2016-05-07 2016-05-07
US201662415954P 2016-11-01 2016-11-01
US201662415918P 2016-11-01 2016-11-01
PCT/US2017/031255 WO2017196657A1 (en) 2016-05-07 2017-05-05 Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

Publications (1)

Publication Number Publication Date
SG11201809858RA true SG11201809858RA (en) 2018-12-28

Family

ID=60267345

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809858RA SG11201809858RA (en) 2016-05-07 2017-05-05 Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
SG10201912837RA SG10201912837RA (en) 2016-05-07 2017-05-05 Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912837RA SG10201912837RA (en) 2016-05-07 2017-05-05 Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

Country Status (15)

Country Link
US (1) US11180731B2 (en)
EP (1) EP3452063A4 (en)
JP (2) JP2019519486A (en)
KR (1) KR20190005964A (en)
CN (1) CN109843304A (en)
AU (2) AU2017262581A1 (en)
BR (1) BR112018072701A2 (en)
CA (1) CA3023239A1 (en)
CO (1) CO2018012923A2 (en)
IL (1) IL262775A (en)
MX (1) MX2018013565A (en)
NZ (1) NZ747910A (en)
SG (2) SG11201809858RA (en)
WO (1) WO2017196657A1 (en)
ZA (1) ZA201807431B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020015512A2 (en) 2018-02-01 2021-01-26 Nkmax Co., Ltd. production method of natural killer cells and composition for cancer treatment
US20220265712A1 (en) * 2019-06-14 2022-08-25 Celularity Inc. Populations of natural killer cells for treating cancers
CN111727961B (en) * 2020-08-10 2020-12-01 医微细胞生物技术(广州)有限公司 Dental pulp stem cell cryopreservation liquid and cryopreservation method thereof
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CN114015653A (en) * 2021-12-15 2022-02-08 山东省齐鲁干细胞工程有限公司 Cryopreserved umbilical cord blood-derived NK (Natural killer) cell and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07135969A (en) * 1993-11-18 1995-05-30 Rikagaku Kenkyusho Precursor cell of natural killer cell and its differentiation and proliferation method
PE20100362A1 (en) * 2008-10-30 2010-05-27 Irm Llc PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
ES2856825T3 (en) * 2011-03-18 2021-09-28 Glycostem Therapeutics B V Generation of NK cells and NK cell progenitors
AU2013212457B2 (en) * 2012-01-27 2017-02-16 Universite De Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
WO2013119118A1 (en) 2012-02-08 2013-08-15 Ipd-Therapeutics B.V. Ex vivo nk cell differentiation from cd34+ hematopoietic cells
KR20150063374A (en) * 2012-08-13 2015-06-09 안트로제네시스 코포레이션 Natural killer cells and uses therof
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof

Also Published As

Publication number Publication date
CN109843304A (en) 2019-06-04
JP2022095927A (en) 2022-06-28
MX2018013565A (en) 2019-08-21
CO2018012923A2 (en) 2018-12-14
WO2017196657A1 (en) 2017-11-16
EP3452063A1 (en) 2019-03-13
EP3452063A4 (en) 2020-01-08
NZ747910A (en) 2023-02-24
US20190153389A1 (en) 2019-05-23
ZA201807431B (en) 2021-09-29
SG10201912837RA (en) 2020-02-27
AU2017262581A1 (en) 2019-01-03
CA3023239A1 (en) 2017-11-16
AU2022287584A1 (en) 2023-02-02
KR20190005964A (en) 2019-01-16
BR112018072701A2 (en) 2019-02-19
IL262775A (en) 2018-12-31
US11180731B2 (en) 2021-11-23
JP2019519486A (en) 2019-07-11

Similar Documents

Publication Publication Date Title
SG11201809858RA (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201907870VA (en) Compositions and methods for inhibition of lineage specific proteins
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201806988UA (en) Improved differentiation method
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201806002SA (en) Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201909331UA (en) Antigen-specific immune effector cells
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201907285XA (en) Methods and kits for generating mimetic innate immune cells from pluripotent stem cells
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201803906PA (en) Control of cellular redox levels
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201806485RA (en) Pyrrolobenzodiazepine conjugates
SG11201403216UA (en) Methods and compounds useful in the synthesis of orexin-2 receptor antagonists